Celcuity

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Saint,Petersburg,,Russia,-,29,March,2020:,Northrop,Grumman,Business

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CELC

NESR

SITC

TYRA

USAR

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Movers_Stocks

CVRX

ELVN

INNV

MAZE

PRTC

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

NMRA

PKST

XPEV

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Celcuity Inc

CelcomDigi Bhd

Earnings

Press Releases

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

Health Care

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

General

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Small Cap

Opinion

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

AMGN

GNTA

ONCY

TSX:ONC

Absci

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Erasca

Heron Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Sage Therapeutics

Sana Biotechnology

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tourmaline Bio

Upstream Bio

Verve Therapeutics

Verastem

Needham

HC Wainwright & Co.

Stifel

LifeSci Capital

Leerink Partners

Comments

Celcuity

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell